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Infections are an important cause of morbidity and mortality in patients with decompensated
cirrhosis and ascites. Hypothesizing that innate immune dysfunction contributes to
susceptibility to infection, we assessed ascitic fluid macrophage phenotype and function.
The expression of complement receptor of the immunoglobulin superfamily (CRIg) and
CCR2 defined two phenotypically and functionally distinct peritoneal macrophage
subpopulations. The proportion of CRIghi macrophages differed between patients and in the
same patient over time, and a high proportion of CRIghi macrophages was associated with
reduced disease severity (model for end-stage liver disease) score. As compared with
CRIglo macrophages, CRIghi macrophages were highly phagocytic and displayed
enhanced antimicrobial effector activity. Transcriptional profiling by RNA sequencing and
comparison with human macrophage and murine peritoneal macrophage expression
signatures highlighted similarities among CRIghi cells, human macrophages, and mouse
F4/80hi resident peritoneal macrophages and among CRIglo macrophages, human
monocytes, and mouse F4/80lo monocyte-derived peritoneal macrophages. These data
suggest that CRIghi and CRIglo macrophages may represent a tissue-resident population
and a monocyte-derived population, respectively. In conclusion, ascites fluid macrophage
subset distribution and phagocytic capacity is highly variable among patients with chronic
liver disease. Regulating the numbers and/or functions of these macrophage populations
could provide therapeutic opportunities in cirrhotic patients.
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Introduction
Most of  the morbidity and mortality in chronic liver disease occurs in patients with advanced fibrosis or 
cirrhosis. Cirrhosis typically has an asymptomatic phase (compensated cirrhosis) followed by a rapidly 
progressive phase (decompensated cirrhosis) signaled by the development of  complications of  liver dys-
function (ascites, variceal bleeding, encephalopathy, jaundice). Patients with decompensated cirrhosis have 
high morbidity and mortality and consequently place a heavy burden on health resources (1). Bacterial 
infections, which occur in one-third of  admitted patients with cirrhosis, account for a 4-fold increase in 
mortality (2), and the high mortality rate after infection (28.6% at 1 month, 63% at 1 year) has not changed 
substantially over recent decades (2, 3).
Ascites, an accumulation of  fluid in the peritoneal cavity, is the most frequent complication of  cirrho-
sis. It is associated with poor prognosis, reduced quality of  life, and increased hospital admissions. Ascites 
fluid is also the most common site of  infection in patients with cirrhosis; spontaneous bacterial peritonitis 
(SBP) occurs in approximately 3% of  outpatients and 10% of  inpatients (2). Increased susceptibility of  cir-
rhotic patients to infection is likely multifactorial, a consequence of  pathological gut bacterial translocation 
and impaired/altered immune function (4). Although thought to be caused by gut bacterial translocation, 
SBP is diagnosed by ascites fluid neutrophil count, as >60% of  SBP cases are culture negative, necessitating 
empirical antibiotic treatment (4). Changing bacterial and resistance patterns in patients with cirrhosis have 
been attributed to the increasing use of  antibiotic prophylaxis and invasive procedures (5, 6), highlighting 
the importance of  ensuring appropriate antibiotic use and of  investigating effective adjunct therapies, such 
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as enhancing immune function. We previously reported that, even in the absence of  overt infection and 
despite SBP prophylaxis, ascites bacterial DNA levels were associated with poor clinical outcomes (death, 
hospital readmission) (7). Bacterial DNA levels were also associated with reduced HLA-DR expression 
on ascites macrophages/monocytes (CD14+ cells), suggesting a reduced antigen presentation capacity (7), 
which may contribute to susceptibility to infection in these patients (8). The presence of  macrophages in 
general, however, correlated with reduced ascites neutrophils and bacterial DNA, suggesting that restoring 
macrophage function (e.g., HLA-DR expression; ref. 9) may be a viable therapeutic strategy.
Studies in peritoneal immunity in mice indicate the presence of  developmentally distinct macrophage 
populations. A Gata6-dependent self-renewing population with a key role in clearing apoptotic cells, coor-
dinating adaptive immunity, and promoting mucosal immunity makes up the majority (~95%) of  resident 
peritoneal macrophages. Gata6-dependent macrophages likely derive from the omentum and self-renew 
by proliferation, while a minor, Gata6-independent resident population probably originate from inflam-
matory monocytes (10–15). Studies in mice also highlight macrophage functional plasticity during perito-
neal inflammation and resolution. Despite existing in the same milieu, macrophages of  different origins 
acquire distinct phenotypes that change throughout the inflammatory response (16, 17), resulting in a state 
of  “adaptive homeostasis,” which lasts for months and dictates the magnitude of  subsequent inflamma-
tory responses (17). These evolving macrophage phenotypes are potentially highly relevant to peritone-
al immunity in patients with chronic liver disease, as peritoneal macrophages are constantly exposed to 
inflammatory stimuli from translocating bacteria due to alterations in intestinal permeability. However, in 
contrast to mice, human peritoneal macrophage phenotype and function has not been extensively studied. 
We hypothesized that human counterparts of  murine resident and inflammatory peritoneal macrophages 
may be present in ascites fluid and play different roles in infection and inflammation, thereby influencing 
clinical outcomes. The aims of  this study were to investigate the phenotype and function of  ascites fluid 
macrophages to gain insight into their contribution to susceptibility to infection in cirrhotic patients and the 
potential to manipulate them for therapeutic benefit.
Results
CRIg and CCR2 distinguish populations of  human peritoneal macrophages in ascites fluid from patients with cirrhosis 
and ascites. We observed that a subpopulation of  macrophages (CD14+ cells) in ascites fluid from patients 
with cirrhosis expressed high levels of  CD14 and the complement receptor for immunoglobulin (CRIg) 
(Figure 1, A and B), which is expressed on several tissue resident macrophage populations (18), including 
the major population of  murine resident peritoneal macrophages (13, 19), and upregulated during human 
monocyte differentiation into macrophages (20). CRIghi cells could frequently be clearly distinguished by 
their high autofluorescence (Supplemental Figure 1; supplemental material available online with this article; 
doi:10.1172/jci.insight.86914DS1), and they did not express CCR2, a classical monocyte marker expressed 
on the minor resident peritoneal macrophage population in mice, which was selectively expressed on 
CRIglo/neg cells (Figure 1, A and C). Together, CRIg and CCR2 afforded complete separation of  the macro-
phage populations (hereafter referred to as CRIghi and CRIglo). The proportion of  CRIghi macrophages in 
ascites fluid differed between patients (median 39.1% [IQR 31.5%] of  CD14+ ascites cells, Figure 1D) and in 
the same patient over time (Figure 1E). A reduction in the proportion of  CRIghi macrophages was observed 
in 3 patients at the time of  cirrhosis related clinical events (SBP, hepatic encephalopathy, and death), and a 
low proportion of  CRIghi ascites macrophages was associated with increased liver disease severity (model for 
end-stage liver disease [MELD] score, spearman r = –0.74, P = 0.002, Figure 1, E and F).
In addition to CRIg expression, the major population of  murine resident peritoneal macrophages is 
characterized by their larger size and relatively high F4/80 expression and low Ccr2, Cd11b, and MHCII 
expression compared with the minor F4/80lo population (10, 14). Infiltrating inflammatory macrophages 
express intermediate (Int.) levels of  F4/80 and variable MHCII levels and are positive for Cd11c and Cd36 
(12, 21). In addition to lacking CCR2 expression, ascites fluid CRIghi macrophages were larger than CRIglo 
macrophages (Figure 2A) and exhibited higher side scatter (Figure 2B). In contrast to mouse peritoneal 
macrophages, CRIghi macrophages expressed the highest levels of  HLA-DR (Figure 2C), and all peritoneal 
macrophages expressed CD11B and CD11C (Figure 2, E and F). CRIghi macrophages also expressed high 
levels of  CD16 (Figure 2D), CD169 (SIGLEC1, Figure 2G), and CD163 (Figure 2H). CRIghi peritoneal 
macrophages thus share some, but not all, of  the phenotypic characteristics of  murine F4/80hi resident 
peritoneal macrophages.
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CRIg+ macrophages exhibit increased phagocytic and microbicidal capacity. Given the role of  CRIg in 
phagocytosis of  pathogens and cellular debris, particularly complement-mediated phagocytosis (20, 
22), we assessed phagocytic and microbicidal function in CRIghi and CRIglo macrophages. CRIghi mac-
rophages engulfed significantly more fluorescently labeled E. coli than did CRIglo macrophages (Figure 
3, A–C; P < 0.0001). Similarly, when infected with live E. coli, intracellular bacterial loads at 1 hour 
(largely reflecting uptake) were higher in CRIghi macrophages compared with CRIglo macrophages (Fig-
ure 3D, fresh human monocyte-derived macrophages [HMDMs] from distinct donors were infected for 
comparison. E. coli survival at 4 hours after infection (relative to uptake at 1 hour) was higher in CRIglo 
macrophages in two-thirds of  experiments, suggesting a reduced microbicidal capacity compared with 
CRIghi macrophages (Figure 3E). Macrophage viability 4 hours after infection, as assessed by extracellular 
lactate dehydrogenase (LDH), was similar in all populations (data not shown), indicating that variation 
in macrophage death did not account for differences in intracellular bacterial loads. Reduced ascites fluid 
macrophage phagocytic capacity was associated with increased disease severity (MELD score, rs = –0.65, 
P = 0.009, Figure 3F). Incubation with E. coli bioparticles increased CRIg surface expression, which was 
further increased in the presence of  autologous ascites fluid, and enhanced E. coli uptake (Figure 3G and 
data not shown; rs = 0.87, P = 0.0002, n = 12).
We further investigated peritoneal macrophage phagocytic capacity using fluorescent latex beads (2 
μM) opsonized with human IgG (to investigate Fc receptor-mediated phagocytosis), serum, heat-inacti-
vated (HI) serum (to investigate complement-mediated phagocytosis), or left unopsonized. We confirmed 
complement C3 deposition on the latex beads after opsonization with serum but not HI serum (data not 
shown). Ascites macrophages were gated on CD14 and CCR2 expression (see Figure 1A), since the strong 
spillover fluorescence from the FitC-labeled beads into the PE channel (required for CRIg staining) could 
not be compensated. Ascites cells were incubated with latex beads for 1 hour in the presence or absence 
of  10 μg/ml Cytochalasin D (which blocks bead internalization by depolymerizing actin) to ascertain the 
relative contributions of  surface-bound and internalized beads to cellular fluorescence (Figure 4, A and B). 
Bead binding was calculated as the percentage of  bead-positive macrophages in the presence of  Cytocha-
Figure 1. CRIg defines a subpopulation of 
macrophages in ascites fluid. (A) Represen-
tative plots showing CD14, CRIg, and CCR2 
expression on cells obtained from ascites fluid 
from 2 cirrhotic patients. CD14–/CRIg– lym-
phocytes are shown for reference; however, 
CD14+ macrophages were gated for analysis 
of fluorescence intensity. (B) CD14 (n = 6) and 
(C) CCR2 (n = 5) median fluorescence intensity 
(MFI) on CRIghi and CRIglo macrophages. 
(Mann-Whitney test). (D) Proportion of CD14+ 
ascites cells expressing CRIg in ascites fluid 
(n = 22, box represents 5th to 95th percen-
tile, with whiskers indicating minimum and 
maximum values and the line at the median). 
(E) Longitudinal variation in the propor-
tion of CD14+ ascites cells expressing CRIg. 
Clinically significant events are annotated 
(n = 6, approximately 3 months between 
paracenteses [“taps”] for each patient). SBP, 
spontaneous bacterial peritonitis; HE, hepatic 
encephalopathy. (F) Correlation between the 
proportion of CD14+ ascites cells expressing 
CRIg and MELD score (n = 15, spearman  
r = 0.74, P = 0.002).
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lasin D. Internalization was estimated by subtracting the proportion of  macrophages that bound the latex 
beads from the total proportion of  bead-positive macrophages in the absence of  Cytochalasin D treatment. 
Opsonization primarily increased bead binding, particularly IgG, although serum increased bead binding 
in comparison to HI serum-opsonized and unopsonized beads, presumably due to complement deposition 
(Figure 4C). Unopsonized and serum-opsonized beads were efficiently internalized, whereas surface bind-
ing appeared to be greater than internalization for IgG-opsonized beads, as treatment with Cytochalasin D 
only modestly reduced the number of  positive cells (Figure 4, C and D). CCR2loCRIghi macrophages bound 
Figure 2. Phenotype of CRIghi human peritoneal macrophages. Representative (A) forward scatter (FSC) and (B) side scatter 
(SSC) histograms and mean area for CRIghi and CRIglo macrophages (n = 12). Representative dot plots showing ascites leukocyte 
expression of CRIg and (C) HLA-DR, (D) CD16, (E) CD11B, (F) CD11C, (G) SIGLEC1, and (H) CD163, and quantification of marker 
expression (median fluorescence intensity [MFI], data represent mean ± SEM) on CRIghi and CRIglo ascites macrophages (CD14+ 
cells, n = 6 except F, for which n = 3; Mann-Whitney test). CRIg– lymphocytes are shown for reference; however, CD14+ macro-
phages were gated for analysis of fluorescence intensity.
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and internalized more of  all bead types compared with CCR2+CRIglo macrophages (Figure 4, C and D).
Transcriptomic analysis of  CRIg+ and CRIglo peritoneal macrophages. In order to further characterize ascites 
fluid macrophages, we profiled flow cytometry-sorted CRIghi and CRIglo macrophages by RNA sequencing 
(n = 6 patients). After filtering out genes with raw count <2 in any sample, 13,431 genes were evaluated for 
differential expression using the DESeq2 and EdgeR algorithms (23, 24). 2,348 genes were identified as sig-
nificantly differentially expressed between the macrophage populations by both algorithms (DESeq2 adjust-
ed P < 0.05, EdgeR FDR < 0.05, 986 ≥ 2-fold; Supplemental Table 1 and Figure 5A). mRNA expression of  
several macrophage markers paralleled their surface expression, with significantly higher CCR2 expression 
in CRIglo macrophages and higher expression of  VSIG4 (encoding CRIg), CD163, and SIGLEC1 in CRIghi 
macrophages. Several transcripts expressed on other tissue macrophage populations, including FCGR1A 
(12) and the efferocytosis receptors MERTK and TIMD4, were also increased in CRIghi macrophages. CRI-
glo macrophages, by contrast, expressed CD36, which is also expressed by infiltrating monocyte-derived 
macrophages in mice (21). Significant differences in transcript structure (exon usage) between the macro-
phage populations were also identified, using the DEXSeq package (25). 1,366 “exons” (counting bins; ref. 
25) in 967 genes were significantly differentially used in CRIghi and CRIglo macrophages (10% FDR, Sup-
plemental Table 2). 23% of  differentially used exons were also differentially expressed genes, while almost 
10% of  differentially expressed genes exhibited significantly different exon usage between macrophage pop-
ulations. Interestingly, the 14 microRNAs (MIRs) that were differentially expressed between CRIghi and 
CRIglo macrophages, including MIRs with well-characterized functions in inflammation, such as MIR21 
(26), were consistently highly expressed in CRIglo cells (Figure 5B).
The Molecular Signatures Database (http://software.broadinstitute.org/gsea/msigdb/index.jsp) pro-
vides a collection of  4,782 immunologic signatures representing cell states and perturbations within the 
immune system defined from microarray gene expression data (collection 7, Human Immunology Project 
Consortium; ref. 27) for gene set enrichment analysis (GSEA). The CRIghi expression signature was most 
similar to the set of  genes that were upregulated in monocytes following 7 days of  culture (normalized 
enrichment score [NES] 3.26, FDR q value 0.0), supporting the view that CRIghi macrophages are a resi-
dent, or more mature, population; whereas CRIglo macrophages most resembled the profile of  uncultured 
Figure 3. Increased microbial phagocytic capacity in CRIg+ macrophages. (A) Representative histograms showing CRIghi and CRIglo fluorescence in the 
absence and presence of pHRodo E. coli bioparticles. (B) Proportion of CRIghi and CRIglo macrophages phagocytosing E. coli bioparticles and (C) change in 
median fluorescence intensity (MFI) with uptake (n = 22, Mann-Whitney test). (D) E. coli phagocytosis (CFU/ml 1 hour after infection, relative to CRIghi 
macrophages) (n = 3, 1-sample t test) and (E) killing capacity (proportion of phagocytosed E. coli [1 hour] surviving at 4 hours) in CRIghi CRIglo and human 
monocyte-derived macrophages (HMDM) (n = 3, Mann-Whitney Test). Dot plot data in B–E represent mean ± SEM. (F) Correlation between ascites fluid 
macrophage phagocytic capacity and MELD score (n = 15, spearman r = 0.65, P = 0.009). (G) Correlation between increased CRIg expression and phagocytic 
capacity in the presence of autologous ascites fluid (fold change compared with incubation in culture medium) (n = 12, spearman r = 0.87, P = 0.0002).
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monocytes (NES 2.67, FDR q value 0.0) (Figure 5, C and D; ref. 28). Providing an in vivo comparison from 
the human peritoneum, Segura et al. recently identified and profiled a distinct population of  CD1C+ mono-
cyte-derived inflammatory DCs from human tumor-associated ascites that promoted Th17 differentiation 
(29) and published gene sets specific to ascites inflammatory DCs and inflammatory macrophages. Given 
that CD1C mRNA was elevated in CRIglo cells by RNA sequencing, we used GSEA to compare ascites fluid 
macrophages to the profiles identified by Segura et al. The macrophage signature was strongly enriched in 
CRIghi macrophages (NES 2.81, FDR q value 0.0), while the inflammatory DC signature was enriched in 
CRIglo macrophages (CD1C+: NES 1.98, FDR q value 0.0) (Supplemental Figure 2, A and B).
We used the Functional Annotation Clustering tool in DAVID (30) to identify significantly enriched 
pathways and gene ontologies in CRIghi or CRIglo macrophages. Lysosomal and cell cycle pathways were 
strongly enriched in CRIghi macrophages, whereas the CRIglo macrophage expression signature was related 
to the inflammatory response (Figure 5E). Lysosome was also the most highly enriched ontology in murine 
F4/80hi resident macrophages compared with inflammatory macrophages (13).
While few studies have examined human tissue macrophage ontogeny, human macrophage activa-
tion states are relatively well studied. Xue et al. recently characterized the human macrophage activation 
spectrum by in vitro stimulation of  monocyte-derived macrophages with a diverse range of  inflamma-
tory stimuli (31). We used GSEA to investigate whether any of  the 49 activation modules identified by 
Xue et al. were enriched in ascites fluid macrophages. Ten modules were significantly enriched in CRIghi 
macrophages, which were associated with glucocorticoid-, IL-4/IL-13-, and lipid-activated macrophage 
signatures. Three modules associated with lipid-, IL-4/IL-13-, and TNF and PGE2-activated macrophage 
signatures were significantly enriched in CRIglo macrophages (Supplemental Table 3). CRIghi and CRIglo 
enriched genes (≥3-fold) formed distinct clusters within the human macrophage activation spectrum, illus-
trating that in vivo macrophages exhibit a complex mixture of  activation signatures and further highlight-
ing the association among CRIglo-enriched genes and inflammatory stimuli and CRIghi-enriched genes with 
antiinflammatory stimuli (Supplemental Figure 2C).
Relationship between ascites fluid macrophages and mouse peritoneal macrophages. We used GSEA to compare 
Figure 4. Increased phagocytic capacity for latex beads in CRIghi macrophages. Representative histograms showing CCR2+ (CRIglo) and CCR2– (CRIghi) 
uptake of (A) unopsonized and (B) IgG-opsonized FitC-labeled latex beads in the absence or presence of 10 μg/ml Cytochalasin D. (C) Latex bead binding 
and (D) internalization capacity in CCR2+ (CRIglo) and CCR2– (CRIghi) macrophages (n = 3, multiple t tests [CCR2+ vs. CCR2–] and repeated-measures 2-way 
ANOVA [serum vs. HI serum], data represent mean ± SEM). HI, heat inactivated.
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ascites fluid macrophage profiles to murine peritoneal macrophage signatures available through the Immu-
nological Genome Project (12, 21). Genes were classified as subset enriched if  they were ≥2-fold more 
highly expressed (Benjamini-Hochberg-corrected P < 0.05) in one population (i.e., F4/80hi with or without 
thioglycollate, F4/80lo with or without thioglycollate, F4/80Int. with or without MHCII expression) com-
Figure 5. Transcriptional profiling of ascites macrophages by RNA sequencing. (A) Volcano plot illustrating genes significantly increased in CRIghi or CRIglo 
ascites macrophages by RNA sequencing (n = 6 patients, DESeq2-generated adjusted P value and fold change). (B) Differentially expressed microRNAs 
(MIR) and macrophage samples were clustered by distance correlation. (C) Macrophage and (D) monocyte gene set enrichment with respect to ascites fluid 
macrophage profile. Ascites macrophage data are ranked according to differential expression between subpopulations (indicated by red-blue bars), and 
the gene set of interest is mapped onto this profile (black bars) to determine enrichment score (green lines). (E) Functional clusters enriched in CRIghi or 
CRIglo macrophages by representative ontology term. The enrichment score represents the log(geometric mean) of the individual enrichment P values of 
members within a functional cluster. A higher enrichment score indicates consistently lower P values for the clustered terms.
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pared with all of  the other macrophage populations (Supplemental Figure 3A). F4/80hi and F4/80lo mac-
rophages were defined by the expression of  189 and 227 genes, respectively; however, only 21 genes were 
uniquely enriched in F4/80Int. macrophages, precluding GSEA of  this population. The F4/80hi expression 
signatures (with or without thioglycollate) were significantly enriched in CRIghi macrophages (NES 1.62, 
FDR q value 0.013). By contrast, the F4/80lo expression signatures (with or without thioglycollate) were 
enriched in CRIglo macrophages (NES 1.99, FDR q value 0.0) (Figure 6, A and B, and Supplemental 
Table 4). Given the most prominent activation signature in both populations of  ascites macrophages related 
to IL-4 stimulation, we further analyzed the relationship between ascites macrophages and alternative-
ly activated resident (induced by IL-4 stimulation) and monocyte-derived (induced by thioglycollate and 
IL-4 stimulation) murine peritoneal macrophages (32, 33), compared with unstimulated and thioglycol-
late-stimulated macrophages. Genes were classified as enriched if  they were ≥2-fold more highly expressed 
(Benjamini-Hochberg-corrected P < 0.05) in one treatment compared with all of  the other 3 treatments 
(Supplemental Figure 3B). Consistent with the similarity between CRIghi ascites macrophages and murine 
resident (F4/80hi) macrophages and the alternative activation signature, the alternatively activated resident 
macrophage signature was highly enriched in CRIghi macrophages (NES 2.6, FDR q value 0.0), while the 
alternatively activated monocyte-derived macrophage signature was modestly enriched in CRIglo macro-
phages (NES 1.3, FDR q value 0.09; Supplemental Figure 3D).
Gata6, a transcription factor that selectively regulates F4/80hi resident peritoneal macrophage expres-
sion and function in mice (14), was expressed at relatively low levels by RNA sequencing in both asci-
tes macrophage populations but was approximately 2-fold more highly expressed in CRIglo macrophages 
(adjusted P = 0.08, Supplemental Table 1). At a global level, genes that were upregulated in murine Gata6 
knockout macrophages, which were associated with alternative activation (11), were strongly enriched in 
CRIghi macrophages (NES 2.23, FDR q value 0.0, Figure 6C). By contrast, genes that were downregulated 
in Gata6 knockout mice, which include peritoneal macrophage-specific transcripts (11, 13), were modestly 
enriched in CRIglo macrophages (NES 1.28, FDR q value 0.088, Figure 6D). Interestingly, E2F and MYC 
target genes were highly enriched in CRIghi macrophages (NES 2.21, FDR q value 0.0 and NES 1.77, FDR 
q value 0.0, respectively), suggesting a role for these transcription factors in CRIghi macrophage develop-
ment or activation.
Gata6 expression in mouse F4/80hi resident peritoneal macrophages, and their capacity to regulate gut 
IgA production through peritoneal B-1 cells, was recently shown to be dependent on vitamin A signaling 
(14). The vitamin A axis is of  significant interest and potential clinical relevance in the setting of  cirrhosis, 
as these patients have impaired mucosal immunity that likely contributes to peritoneal bacterial transloca-
tion (34) and are frequently vitamin A deficient (35); however, vitamin A signaling in human peritoneal 
macrophages has not been investigated. We treated flow cytometry-sorted CRIghi and CRIglo macrophages 
with all-trans retinoic acid (ATRA) for 6 or 24 hours and quantified expression of  murine retinoic acid 
responsive genes (14). GATA6 mRNA was more highly expressed in cultured CRIglo macrophages compared 
with CRIghi macrophages but was not induced by ATRA (Figure 6E). Similarly, in mice, Gata6 is only 
retinoic acid inducible in fetal, but not adult, macrophages, and it is postulated that mature macrophages 
have undergone epigenetic changes that prevent Gata6 induction (14, 36). With the exception of  TGFB2 and 
ARG1 (which was not detected by RNA sequencing or qPCR), all selected genes (CXCL13, LGR1, RARB, 
RAI14, and ITGA6 [CD49F]) were more highly expressed and/or ATRA inducible in CRIglo macrophages 
compared with CRIghi macrophages (Figure 6, F–K). Although not differentially expressed in unstimulated, 
sorted macrophage populations at the transcript level (Figure 6K), surface CD49F (a Gata6 target in mice; 
ref. 14) was elevated on CRIghi cells (Figure 6L). Together, these data suggest a more prominent role for reti-
noic acid signaling in CRIglo macrophages compared with CRIghi macrophages, although the role of  GATA6 
Figure 6. Relationship between human and murine peritoneal macrophage signatures. (A and B) Murine peritoneal macrophage-specific gene set 
enrichment with respect to the ascites fluid macrophage profile. Ascites macrophage data are ranked according to differential expression between 
subpopulations (indicated by red-blue bars), and the gene set of interest is mapped onto this profile (black bars) to determine enrichment score 
(green lines) (Thio., thioglycollate). Enrichment of genes (C) upregulated and (D) downregulated in murine Gata6-deficient macrophages in ascites 
macrophages (GSEA analysis as in A). Relative expression of (E) GATA6, (F) TGFB2, (G) CXCL13, (H) LRG1, (I) RARB, (J) RAI14, and (K) CD49F in CRIghi 
and CRIglo macrophages stimulated with ATRA (n = 3, repeated-measures 2-way ANOVA followed by Sidak multiple comparison test for differ-
ences between macrophage populations or time point). (A–J) ANOVA P values for the effect of macrophage population or (K) ATRA stimulation 
on gene expression; *P < 0.05, **P < 0.01. (L) Mean fluorescence intensity (MFI) of CD49F surface expression on ascites macrophage populations 
(Mann-Whitney test, n = 6) and representative dot plot. Dot plot data represent mean ± SEM.
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is not known. In support of  this, we performed a connectivity map analysis (37) to identify potential drugs 
that induced the CRIghi or CRIglo macrophage signature, and the strongest drug class association was the 
topical retinoids (D10AD), predicted to favor the CRIglo macrophage profile (P = 0.00046).
Discussion
New strategies are needed to prevent recurrent infections, minimize the use of  empirical antibiotics, and 
improve outcomes for patients with cirrhosis. Therapeutic manipulation of  the host immune response may 
be a viable strategy; however, the mechanisms and clinical relevance of  peritoneal immune function and 
dysfunction require clarification. Although acute and chronic peritoneal inflammation has been extensive-
ly studied in mice, and developmentally distinct resident and inflammatory peritoneal macrophages have 
been characterized in detail, human peritoneal macrophages have not been widely studied. Here, we have 
identified 2 phenotypically and functionally distinct human peritoneal macrophage subpopulations in asci-
tes fluid from cirrhotic patients, in the absence of  overt infection, which can be clearly distinguished on the 
basis of  CRIg and CCR2 expression. Our data suggest the presence of  CRIghi macrophages (or absence of  
CRIglo macrophages) is associated with improved liver status and better prognosis. Future studies will be 
required to determine the peritoneal macrophage phenotype in noncirrhotic patients, in order to under-
stand whether CRIghiCCR2– and CRIgloCCR2+ cells are developmentally distinct and/or shaped by perito-
neal inflammation.
If  monocyte-dependent and -independent macrophages are present in ascites fluid as in the mouse 
peritoneum, in health and disease, several lines of  evidence support the hypothesis that CRIghi macro-
phages are, or contain, the human counterparts of  murine F4/80hi resident peritoneal macrophages. First, 
F4/80hi macrophages express high levels of  CRIg/Vsig4; whereas Ccr2, that defines CRIglo macrophages, 
is expressed on monocyte-derived macrophages (13, 14). Second, at a transcriptomic level, when com-
pared with human immune cell expression profiles, CRIghi macrophages were highly enriched for mature 
macrophage transcripts and resembled macrophages from human tumor ascites fluid, whereas CRIglo cells 
exhibited a monocytic signature and resembled inflammatory monocyte-derived DCs found in tumor asci-
tes fluid (29). Similarly, CRIghi macrophages were significantly, albeit modestly, enriched for genes that 
define F4/80hi mouse macrophages, while the F4/80lo macrophage expression signature was enriched in 
the CRIglo population. Third, the strong cell cycle signature in CRIghi macrophages is consistent with the 
hypothesis that these cells are a self-renewing, tissue-resident population (15) — although it should be not-
ed that both bone marrow-derived and tissue-resident macrophage lineages proliferate at different stages 
during inflammation in mice (38, 39).
Despite the similarities between CRIghi and F4/80hi macrophages, some of  our data point to simi-
larities between CRIglo and F4/80hi macrophages. GATA6, a master transcriptional regulator of  F4/80hi 
resident macrophages (11, 13, 14), was more highly expressed in CRIglo macrophages compared with 
CRIghi ascites macrophages, as were murine Gata6-dependent genes (11). Expression of  Gata6 itself  and 
several of  its target genes is vitamin A-dependent in mouse macrophages (14). Four of  six selected murine 
Gata6/retinoic acid target genes were also ATRA inducible in ascites macrophages, all of  which were more 
highly expressed/inducible in CRIglo macrophages compared with CRIghi macrophages. If  GATA6 fulfils 
the same function in humans as in mice, these data suggest an alternative hypothesis — that CRIghi and 
CRIglo macrophages are subsets of  one major human resident peritoneal population that is equivalent to 
murine F4/80hi macrophages, since both populations express VSIG4 and GATA6, although at different lev-
els. CRIghi macrophages may upregulate CRIg, and downregulate CCR2 and GATA6, during maturation 
in the ascites microenvironment. Indeed, we observed surface CRIg upregulation when ascites cells were 
incubated with E. coli bioparticles, especially in autologous ascites fluid. Similarly in mice, zymosan-in-
duced peritonitis upregulated Vsig4 mRNA (13), and thioglycollate activation also induced Vsig4 in F4/80hi 
resident peritoneal macrophages (GSE15907; ref. 21). Finally, if  GATA6 does not define monocyte-inde-
pendent peritoneal macrophages in humans, it is possible that the ascites macrophages studied here are 
monocyte derived, akin to the F4/80lo murine population, and the omentum-derived resident population, if  
it exists, remains to be identified. Future investigations, potentially using additional markers to those iden-
tified here, will be important to refine ascites macrophage phenotypes and clarify their origin and function 
to confirm their relationship to murine peritoneal macrophages.
Our data suggest that ascites fluid macrophages are associated with clinical parameters and potential-
ly clinical outcomes. An increased proportion of  CRIghi macrophages in ascites fluid, and a reciprocally 
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low proportion of  CRIglo macrophages, correlated with lower MELD scores. In mice, F4/80hi resident 
macrophages disappear during acute inflammation, while infiltrating monocytes augment the macrophage 
compartment, so alterations in relative macrophage proportions may simply be indicative of  peritoneal 
inflammation in patients. CRIg itself  is a multifunctional protein that promotes phagocytosis of  C3-op-
sonized microbes and apoptotic cells in conjunction with CR3, enhances killing of  intracellular bacteria 
(40), and also possesses antiinflammatory and immunosuppressive functions (19, 20, 22, 41–44). CRIghi 
macrophages may beneficial due to their superior phagocytic and microbicidal capacity, due to other anti-
inflammatory functions mediated by CRIg, or for reasons unrelated to CRIg expression. CRIghi macro-
phages were enriched for IL-4-related human macrophage activation modules (31), the murine alternatively 
activated resident macrophage signature (33), and genes that were upregulated in murine Gata6 knockout 
macrophages, which have been associated with alternative activation (11). Given their high phagocytic 
capacity and antiinflammatory activation signature, the data could suggest that CRIghi macrophages are 
“alternatively activated,” which may relate to the negative correlation between CRIghi macrophages and 
MELD score. Alternative activation, a critical component of  type 2 immunity, also contributes to the main-
tenance of  tissue and metabolic homeostasis (45). Additionally, or alternatively, CRIglo macrophages may 
be disadvantageous due to their inflammatory nature and reduced phagocytic and microbicidal function. 
In addition to the implications for host defence, sustained peritoneal inflammation may also contribute to 
impaired lymphatic function and peritoneal fluid drainage, which was promoted by infiltrating, inflamma-
tory Ccr2-dependent macrophages in a mouse model of  peritonitis (46, 47).
Consistent with CRIg’s antiinflammatory functions, VSIG4 gene expression is upregulated by antiinflam-
matory stimuli such as IL-10 and dexamethasone and downregulated by proinflammatory stimuli such as 
IFN-γ and TNF in vitro and in vivo (48–50). Although increased transcription and translation could conceiv-
ably contribute to the CRIg induction we observed in ascites fluid, other as-yet-unknown factors regulating 
surface CRIg expression are likely involved. Importantly, these data suggest the importance of  modifiable 
factors that could potentially be harnessed to enhance peritoneal macrophage function in cirrhotic patients. 
CSF-1 controls proliferation of  resident and recruited peritoneal macrophages in mice, and IL-4 may also play 
a role in some settings (38, 51). Ascites macrophages expressed both CSF1R and IL4R, with higher levels of  
CSF1R mRNA and surface expression (data not shown) in CRIghi macrophages. Given that CSF-1 has been 
extensively developed as a therapeutic target (52) and was recently associated with good outcomes in patients 
with acute liver failure and demonstrated to promote liver regeneration in mice (53), CSF-1 treatment may 
represent a viable therapeutic strategy. Interestingly, CRIghi macrophages exhibited a prominent IL-4 acti-
vation signature, although this was observed in both ascites macrophage populations. In contrast to the role 
of  vitamin A in promoting intestinal homeostasis in mice, our data suggest that vitamin A signaling favors 
the CRIglo macrophage profile, which was associated with higher MELD scores in our cohort. However, 
understanding the contribution of  macrophage origin to eventual function, and the relative contributions of  
recruitment and proliferation to inflammatory responses, will be critical for macrophage-targeted therapy.
In conclusion, we report the presence of  distinct peritoneal macrophage subpopulations, which may 
contribute to the poor outcomes experienced by patients with cirrhosis and ascites. Understanding the 
dynamics, functions, and clinical relevance of  these populations may provide novel therapeutic approaches 
to improve clinical outcomes.
Methods
Patients and ascites fluid collection. Ascitic fluid (2–4 liters) was collected from patients with decompensated cir-
rhosis undergoing therapeutic paracentesis at the Princess Alexandra Hospital. Standard biochemical and sero-
logical assays, liver imaging, and histological assessment of a liver biopsy (if  performed) were used to confirm 
diagnosis of liver disease and cirrhosis. Clinical data were obtained by review of patient medical records. Liver 
disease severity was evaluated using MELD (3.78×ln[serum bilirubin {mg/dL}] + 11.2×ln[INR] + 9.57×ln[se-
rum creatinine {mg/dL}] + 6.43; ref. 54). Of the 6 patients selected for RNA sequencing, all were of mixed 
European descent, mean age was 62.9 (SD 8.9), 4 were male, 3 had alcoholic liver disease, 2 had nonalcoholic 
steatohepatitis, and 1 had chronic HCV infection complicated by alcohol use. Ascites fluid cells were harvested 
by centrifugation (400 g for 5 minutes) and cryopreserved in medium containing 90% FBS/10% DMSO.
Flow cytometry. For cell phenotyping, 0.5 × 106 to 1 × 106 cells were resuspended in FACS buffer 
(PBS/1% FBS/5 mM EDTA) and stained with optimized panels comprising combinations of  the follow-
ing antibodies, with the addition of  Live/Dead Aqua (Thermo Fisher) for dead cell discrimination in some 
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experiments, on ice for 30 minutes in the dark: CD14-BV421 (M5E2), CD14-APC (M5E2), CD163-PerCP-
Cy5.5 (GHI/61), HLA-DR-FITC (L243), CD62L-FITC (DREG-56), SIGLEC-1-APC (7-239), CD11B-
APC (ICRF44), and CSF1R-PE (9-4D2-1E4) (all BioLegend); CD16-APC-H7 (3G8; BD Biosciences); 
CCR2-APC (48607) and CD49F-AF488 (GoH3) (both R&D Systems); and CRIg-PE (6H8, Santa Cruz). 
Samples were washed in FACS buffer and resuspended in FACS buffer containing 1% PFA for analysis. 
Isotype controls were employed during panel development (Supplemental Figure 1), and unstained and 
single color controls were routinely performed to generate compensation matrices to correct for spectral 
overlap and facilitate gating. Samples were acquired on a Gallios flow cytometer, and data were analyzed 
using Kaluza software (Beckman Coulter). For cell sorting, cells were labeled with CD14-BV421 or CD14-
APC and CRIg-PE and sorted into FBS-coated polystyrene tubes using a MoFlo Astrios sorter (Beck-
man Coulter), achieving >90% purity. Since CRIg staining did not completely separate the populations in 
every patient sample, we routinely sorted CRIghi and CRIglo cells, avoiding the region of  potential overlap 
between the populations. For analysis and sorting, dead cells/debris were excluded by their low FSC/high 
SSC profile or high Live/Dead Aqua (Life Technologies) staining, and doublets were excluded using FSC-
Height versus FSC-Area or time-of-flight. Negative gates were set based on unstained samples and compen-
sated single color controls (Supplemental Figure 1). CD14 was used to define monocytes/macrophages for 
quantitation of  surface marker expression, although plots show all ascites leukocytes for reference.
Opsonization, phagocytosis, and infection assays. pHrodo E. coli BioParticles (Molecular Probes) were add-
ed to ascites cells in 5-ml flow cytometry tubes at a ratio of  10:1 and incubated at 37°C for 1 hour, with 
antibodies to cell surface markers added after 30 minutes. Cells were washed twice with cold FACS buffer 
prior to acquisition. FitC-labeled carboxylated polystyrene beads (2 μm; Sigma-Aldrich) were diluted to 
0.5% solids in PBS, human IgG (10 mg/ml; Sigma-Aldrich), human AB serum (Sigma-Aldrich), or HI AB 
serum (45 minutes at 56°C) and incubated for 2 hours at 37°C. Beads were added to ascites cells resuspend-
ed in serum-free DMEM, pretreated for 20 minutes with 10 μg/ml Cytochalasin D (Sigma-Aldrich) or left 
untreated, at a ratio of  10:1 and incubated for 1 hour at 37°C, with the addition of  antibodies to cell surface 
markers after 30 minutes. Cells were washed twice with cold FACS buffer and resuspended in FACS buffer 
with 1% PFA for analysis. Bead and bioparticle phagocytosis were analyzed using a Gallios flow cytometer 
and Kaluza analysis software (Beckman Coulter). Complement C3 deposition following serum opsoniza-
tion was confirmed by staining opsonized beads with anti-human C3 (1H8, Cedarlane) followed by an anti-
mouse Alexa647 secondary antibody (Molecular Probes) and analyzed by flow cytometry.
Bacterial infection assays were conducted in HMDMs and CRIghi/lo macrophages as previously described 
(55). In brief, in vitro-differentiated HMDMs or flow cytometry-sorted ascites cells were cultured at 2 × 105 
cells/well in 1 mL antibiotic-free tissue culture media at 37°C overnight prior to infection with E. coli (strain 
MG1655) at a MOI of  10. At 1 hour after infection, cells were washed with media containing 200 μg/mL 
gentamicin (gentamedia) to exclude extracellular bacteria and then maintained for 1 hour in 200 μg/mL 
gentamedia. Cells were then washed with and maintained in 20 μg/mL gentamedia for a further 3 hours. 
Cells were harvested in 0.01% Triton X-100 in PBS and lysed by pipetting. Diluted lysates were cultured on 
LB agar plates at 37°C overnight, and colony counts were used to assess intracellular bacterial loads. Culture 
supernatants were collected to assess cell death through the release of  the metabolic enzyme, LDH, from 
dying cells into culture supernatants. LDH release was quantified by measuring LDH in culture supernatants 
in comparison to total LDH (LDH present in supernatants from untreated cells following cell lysis with 0.1% 
Triton X-100), as previously described (56).
RNA purification, ATRA stimulation, and qPCR. Total RNA was purified using RNA Nucleospin col-
umns (Machery Nagel). For ATRA stimulation, flow cytometry-sorted CRIghi and CRIglo macrophages 
were seeded in 12-well plates (0.5e6/well) in RPMI containing 10% FBS and Penicillin/Streptomycin and 
allowed to adhere for 2 to 4 hours. Cells were treated with 10 μM ATRA (Sigma-Aldrich) or vehicle control 
(DMSO, Sigma-Aldrich) 24 or 6 hours prior to harvest in lysis buffer for RNA purification. cDNA was 
synthesized using Superscript III (Invitrogen) with oligo dT priming. qPCR was performed using SYBR 
Green PCR Mastermix (Applied Biosystems) and a ViiA 7 real-time PCR system (Applied Biosystems). 
Gene expression relative to hypoxanthine-guaninephosphoribosyltransferase (HPRT) was quantified using 
the ΔCt method. The following primers were used in this study: HPRT-F TGCTGGATTACATCAAAG-
CACTG, HPRT-R CCCCTGTTGACTGGTCATTACAA, LRG1-F CAGGACAACCCAGAAG-
CAAAAG, LRG1-R TCTAGAAACATGGGGTTGAATGC, ARG1-F TCAACACTCCACTGACAAC-
CACA, ARG1-R AATCCTGGCACATCGGGAATC, GATA6-F ACTTCCCCCACAACACAACCT, 
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GATA6-R AGCTCGCTGTTCTCGGGATT, RAI14-F CAGCAAGTCAAACAGCTCCAGA, RAI14-R 
GCCCTGCACAGCATACAGAAG, RARB-F ATCAGAAAAAGACGACCCAGCA, RARB-R 
AGGTAATTACACGCTCTGCACCTT, CD49F-F TATTCGGGAGTACCTTGGTGGA, CD49F-R 
AGCGTTTAAAGAATCCACACTTCC, TGFB2-F GGATGCGGCCTATTGCTTTAGA, TGFB2-R 
TCGTGTATCCATTTCCACCCTAGA, CXCL13-F AATTGTGTGTGTGGACCCTCAA, CXCL13-R 
GGGAATCTTTCTCTTAAACACTGGAA.
RNA sequencing and data analysis. RNA sequencing was performed by the University of  Queensland 
IMB Sequencing Facility. Libraries were generated from 500 ng total RNA (Agilent Bioanalyzer RNA 
Integrity values ≥8) using TruSeq Ribo-Zero GOLD RNA Library Preparation Kit Set A and Set B (Illu-
mina, catalog RS-122-2301 and RS-122-2302) and sequenced on a 1×75 bp High Output V2 run (Illumina, 
catalog FC-404-2005) using a NextSeq500 sequencing system (Illumina, NextSeq control software v1.4/
Real Time Analysis v2.1). A total of  475.7 million reads were obtained, with 28.3 million to 58.2 million 
reads per replicate, and 95.3% of  base calls achieved an Illumina Q score ≥Q30. Sequencing reads were 
mapped to UCSC human genome version hg19, using STAR v2.3.0e (57) with 25.7 million to 52.3 million 
uniquely mapped reads per replicate, and the SAM output was converted to BAM format using samtools 
v0.1.19 (58). Gene read counts were obtained using the HTSeq python package (59). Differential expres-
sion was detected using the DESeq2 (60) and EdgeR (24) R packages and filtered to remove genes with 
<2 counts in any replicate (retaining 13,431 expressed genes). Differentially expressed genes (n = 2,348) 
were defined as genes that were identified as differentially expressed using both the DESeq2 (adjusted P < 
0.05, n = 3,634) and EdgeR (FDR < 0.05, n = 2,373) algorithms. The RNA sequencing data are available 
in the GEO repository under accession number GSE79833. GSEA was performed using GSEA v 2.10 
using gene set permutation and default settings. Gene sets used for analysis were from immune collection 
from the MSIG database (27), Segura et al. (29), Xue et al. (31), Gautier et al. (11), Gundra et al. (33), and 
the Immgen consortium (21) (see below). Gene ontology analysis was performed using DAVID (https://
david.ncifcrf.gov/) with default parameters. Connectivity map analysis was performed using the tool at 
http://www.broadinstitute.org/cmap (37) with default parameters. To identify murine peritoneal macro-
phage subset-enriched genes, samples corresponding to the major (F4/80hiMHCII-) and minor (F4/80loM-
HCII+) resident populations under basal conditions and following thioglycollate activation as well as the 
infiltrating F4/80Int.MHCII+ and F4/80Int.MHCII- populations were downloaded from the Immunological 
Genome Project (GSE15907; ref. 21) and analyzed using Genespring GX. Data from GSE54679 (33) were 
analyzed to identify genes enriched in unstimulated, thioglycollate-activated, IL-4-activated, and IL-4 and 
thioglycollate-activated murine peritoneal macrophages using Genespring GX.
Statistics. Statistical analyses were performed in Graph Pad Prism (version 6.04; GraphPad Soft-
ware Inc.), utilizing the Mann-Whitney test for pairwise comparisons, ordinary and repeated-measures 
2-way ANOVA with Tukey’s multiple comparisons test for multiple comparisons, 1-sample t test for data 
normalized to control (comparison to the hypothetical mean of  1.0), and Spearman’s rank-correlation 
coefficient. All comparisons were 2-tailed and a P value of  less than 0.05 was defined as the level of  sig-
nificance. All data are represented as mean ± SEM.
Study approval. Informed written consent was obtained from each patient prior to inclusion in the study, 
and the protocol was approved by the Metro South Health and The University of  Queensland Human 
Research Ethics Committees.
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